Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HM-225: Measurable Residual Disease (MRD) Guided De-intensification of Bendamustine/Rituximab (BR) for Indolent Non-Hodgkin Lymphoma

NCT06557330 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT06557330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06557330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HM-225: Measurable Residual Disease (MRD) Guided De-intensification of Bendamustine/Rituximab (BR) for Indolent Non-Hodgkin Lymphoma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 30, 2025
Completion date
March 30, 2028
Enrollment
24 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non-hodgkin lymphoma, lymphoma